Your Cholesterol Result, Decoded: HDL, LDL, ApoB and Lp(a) in Plain English

Your cholesterol result is not one number. It is several different stories, and many people are told only the headline.

A standard cholesterol panel is a sensible starting point. It may not be the whole cardiovascular picture, particularly when heart disease runs in the family or the standard results do not fit the person's apparent risk.

When a reassuring result may be incomplete

A standard panel can show total cholesterol within range, an unremarkable LDL and a healthy HDL while leaving an important question unanswered. This is particularly relevant when a parent or sibling developed cardiovascular disease at a young age despite apparently acceptable cholesterol results.

The missing information may be an inherited Lp(a) level, a higher-than-expected number of ApoB-containing particles or another risk factor outside the lipid panel.

This does not mean that everyone with a normal cholesterol result is in danger. It means that a result needs context, especially when the family history and the standard numbers tell different stories.

By the end of this guide, you should understand every line of a standard lipid panel, what ApoB adds and why lipoprotein(a) is often worth measuring once.

Start with the cargo analogy

Cholesterol is a waxy substance needed for cell membranes, hormones and bile acids. Because fat does not dissolve in water, cholesterol cannot travel freely through the bloodstream. It is carried inside protein-wrapped packages called lipoproteins.

Think of cholesterol as the cargo and lipoproteins as the vehicles carrying it. A standard panel mainly estimates how much cargo is being transported. ApoB gives information about the number of potentially plaque-forming vehicles.

Total cholesterol: the blunt headline

Total cholesterol combines cholesterol carried in several types of particle. On its own, it does not show how much is carried in LDL, HDL and other lipoproteins.

Two people can have the same total cholesterol and different cardiovascular risks. A result around 5.0 mmol/L (about 190 mg/dL) may be acceptable for one person and concerning for another, depending on the breakdown and the company it keeps: blood pressure, diabetes, smoking, kidney disease, family history and existing arterial disease.

Cholesterol is reported in different units in different countries. Laboratories in the UK, Ireland and much of Europe use millimoles per litre (mmol/L); laboratories in the United States use milligrams per decilitre (mg/dL). This guide gives both. To convert cholesterol, HDL, LDL or non-HDL from mmol/L to mg/dL, multiply by about 38.7; for triglycerides, multiply by about 88.6. The figures below are rounded.

If you are given only a total result, ask for the full lipid profile.

LDL: the foundational treatment target

LDL stands for low-density lipoprotein. LDL particles transport cholesterol through the blood. When too many circulate for too long, more cholesterol can enter the artery wall and contribute to plaque.

This cumulative exposure matters. LDL does not need to cause symptoms to cause harm, and one acceptable result today does not erase years of higher exposure.

On many standard panels, LDL is calculated rather than measured directly. The estimate can become less reliable when triglycerides are markedly raised. This is one reason non-HDL cholesterol and, in selected cases, ApoB can add useful information.

What counts as a good LDL?

There is no single ideal LDL for everyone. The appropriate target depends on cardiovascular risk.

As broad European reference points:

• a lower-risk person may have an LDL goal around 3.0 mmol/L (about 116 mg/dL)
• moderate risk may justify a goal around 2.6 mmol/L (about 100 mg/dL)
• high risk may require a goal around 1.8 mmol/L (about 70 mg/dL)
• very high risk, including many people with established cardiovascular disease, may require LDL below 1.4 mmol/L (about 55 mg/dL) together with a substantial reduction from baseline

UK NICE guidance uses a somewhat different framework. In primary prevention, the decision to offer treatment is driven by overall cardiovascular risk, and response is often assessed by aiming for a reduction of more than 40% in non-HDL cholesterol. In secondary prevention, NICE currently aims for LDL of 2.0 mmol/L or below (about 77 mg/dL) or non-HDL cholesterol of 2.6 mmol/L or below (about 100 mg/dL).

Different frameworks do not mean that the biology changes at a national border. They reflect different risk categories and healthcare-system decisions. Ask which target your clinician is using for you.

There is no universal normal LDL. The right number depends on the company it keeps.

Non-HDL: a useful number hiding in plain sight

Non-HDL cholesterol is total cholesterol minus HDL cholesterol. It includes LDL and cholesterol carried by other potentially plaque-forming particles.

It has practical advantages:

• it can be calculated from a standard panel
• it usually does not require fasting
• it captures more atherogenic cholesterol than LDL alone
• it is used by NICE to assess response to treatment

For otherwise healthy adults, non-HDL below 4.0 mmol/L (about 155 mg/dL) is a broad general guide. People with established cardiovascular disease need a lower target.

HDL: useful information, but not a cancellation credit

HDL stands for high-density lipoprotein. HDL participates in carrying cholesterol away from tissues towards the liver, which led to the nickname “good cholesterol”.

General healthy-adult reference values commonly use HDL above 1.0 mmol/L for men (about 40 mg/dL) and 1.2 mmol/L for women (about 45 mg/dL).

However, a high HDL does not cancel a raised LDL or ApoB. Very high HDL is not necessarily an extra layer of protection, and treatments designed merely to raise HDL have not consistently prevented cardiovascular events.

The practical priority remains controlling atherogenic particles and the person's total risk.

Triglycerides: the metabolic clue

Triglycerides are a different type of blood fat used to transport and store energy. They may rise with insulin resistance, diabetes, excess alcohol, excess weight, some medicines and genetic conditions.

As a general guide, fasting triglycerides below 1.7 mmol/L (about 150 mg/dL) are desirable. A non-fasting value may be somewhat higher. Very high levels need prompt clinical assessment because they can increase the risk of pancreatitis.

Raised triglycerides can also make a calculated LDL less reliable and may be a reason to assess the wider metabolic picture.

What about the triglyceride-to-HDL ratio?

The triglyceride-to-HDL ratio is calculated by dividing triglycerides by HDL using the same units. A higher ratio is associated with insulin resistance and an adverse lipoprotein pattern in population studies.

It can be a free clue within the standard panel, but it is not a diagnosis and is not a principal treatment target in current UK or European guidelines. Thresholds vary by sex, ethnicity and unit system, so it should not be interpreted as a universal pass-or-fail number.

If triglycerides are raised and HDL is low, it is more useful to discuss diabetes risk, waist circumference, blood pressure, non-HDL cholesterol and whether ApoB would change management.

ApoB: counting particles rather than cargo

Every major atherogenic particle carries one molecule of apolipoprotein B. Measuring ApoB therefore provides an estimate of the number of potentially plaque-forming particles rather than the amount of cholesterol cargo inside them.

Why does that matter? Two people can have the same LDL cholesterol and different particle numbers. This discordance is more common with:

• high triglycerides
• type 2 diabetes
• insulin resistance or metabolic syndrome
• obesity
• some inherited lipid disorders
• established cardiovascular disease despite apparently controlled LDL

ApoB is directly measured, does not usually require fasting and is well standardised. It does not replace LDL as the foundational treatment target, but it can refine risk when the standard measures and the clinical picture disagree.

The 2026 ACC/AHA multisociety dyslipidaemia guideline gives ApoB a formal role as an additional marker in selected patients. In UK practice it is not included in most routine panels.

A sensible order is:

1. Measure the standard lipid profile.
2. Address clearly raised LDL or non-HDL cholesterol.
3. Consider ApoB when residual or discordant risk might change the plan.

Two people can share an LDL number and carry different numbers of particles. ApoB helps tell them apart.

Lp(a): the inherited number usually measured once

Lipoprotein(a), written Lp(a) and pronounced “L-P-little-a”, is an LDL-like particle with an additional apolipoprotein(a) component. Raised levels are associated with atherosclerotic cardiovascular disease and narrowing of the aortic valve.

Three features make it unusual:

1. The level is determined largely by genetics.
2. It remains relatively stable across adult life.
3. Diet and exercise have little effect on it.

This is why Lp(a) generally needs to be measured only once, unless a specialist identifies a reason to repeat it.

As a broad guide:

• below 75 nmol/L (about 30 mg/dL) is generally lower risk
• 75–125 nmol/L (about 30–50 mg/dL) is an intermediate range
• above 125 nmol/L, or about 50 mg/dL, is associated with meaningfully higher cardiovascular risk

The conversion between nmol/L and mg/dL is only approximate because the size of Lp(a) particles varies. Interpret the result in the units reported by the laboratory.

What can be done about a raised Lp(a)?

A raised Lp(a) is not a sentence and should not be treated in isolation. Its immediate value is to refine overall risk and support more determined control of factors that can be modified, including:

• LDL and ApoB-containing particles
• blood pressure
• diabetes and smoking
• weight and physical activity
• treatment adherence

Several medicines designed specifically to lower Lp(a) are in advanced clinical trials. As of July 2026, the large Lp(a)HORIZON outcomes trial of pelacarsen remains ongoing, and no treatment is yet licensed specifically on the basis that lowering Lp(a) has been proven to reduce cardiovascular events.

We know that Lp(a) is associated with risk. The outcomes trials are testing whether specifically lowering it prevents events.

Which tests can you get in the UK?

The standard lipid panel is routinely available through NHS primary and secondary care.

ApoB is not yet part of most routine NHS panels. It may be available in specialist lipid services or privately when the result is likely to influence management.

Lp(a) is increasingly requested when there is:

• premature cardiovascular disease
• a strong family history
• suspected familial hypercholesterolaemia
• unexpectedly severe disease
• uncertainty about risk despite standard testing

The 2026 US guideline supports measuring Lp(a) at least once during adulthood. Availability and routine practice vary in the UK, but it is reasonable to ask whether the result would help refine your risk.

What to do with your result

1. Get the basics first. Ask for the full lipid profile, not only total cholesterol.
2. Know your LDL and non-HDL. Ask which target applies to your level of risk.
3. Treat what is already clear. If LDL is above target, do not delay effective treatment while searching for more exotic markers.
4. Consider ApoB when the picture is discordant. It is most useful when particle number might be higher than LDL suggests.
5. Measure Lp(a) once when appropriate. Family history and premature disease make the result particularly relevant.
6. Read every number in context. No single marker diagnoses coronary disease.

Three things you can do this week

1. Find your most recent cholesterol result and identify total cholesterol, HDL, non-HDL, LDL and triglycerides.
2. Ask what target applies to you rather than whether the result is merely “in range”.
3. Record any heart attack or stroke in a parent or sibling, including the age at which it occurred, and discuss whether ApoB or Lp(a) would change your assessment.

You cannot manage what has never been measured. The right numbers, interpreted properly, can shape decisions for decades.

---

Medical note: This article provides general education. Lipid targets, additional tests and treatment decisions require an individual cardiovascular-risk assessment.

Sources

• NICE NG238: Cardiovascular disease risk assessment and lipid modification
• ESC 2025 Focused Update on dyslipidaemias
• 2026 ACC/AHA multisociety dyslipidaemia guideline hub
• ClinicalTrials.gov: Lp(a)HORIZON, NCT04023552
• British Heart Foundation: Understanding cholesterol levels